Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)

Imagem de Miniatura
Arquivos
art_ROBAK_Association_between_bortezomib_dose_intensity_and_overall_survival_2019.PDF (1.31 MB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2019
Editora
TAYLOR & FRANCIS LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
ROBAK, Tadeusz
HUANG, Huiqiang
JIN, Jie
ZHU, Jun
LIU, Ting
SAMOILOVA, Olga
PYLYPENKO, Halyna
VERHOEF, Gregor
SIRITANARATKUL, Noppadol
OSMANOV, Evgenii
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
LEUKEMIA & LYMPHOMA, v.60, n.1, p.172-179, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed >= 6 cycles of treatment. From the end of cycle 6, patients receiving >= 4.6 mg/m(2)/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m(2)/cycle by univariate analysis (HR 0.43 [95% CI: 0.23-0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20-0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.
Palavras-chave
Mantle cell lymphoma, R-CHOP, VR-CAP, bortezomib, LYM-3002, dose intensity
URI
https://observatorio.fm.usp.br/handle/OPI/31102
Referências
  1. Bosly A, 2008, ANN HEMATOL, V87, P277, DOI 10.1007/s00277-007-0399-y
  2. Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E
  3. Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403
  4. Dreyling M, 2014, ANN ONCOL, V25, P83, DOI 10.1093/annonc/mdu264
  5. EPELBAUM R, 1988, ISRAEL J MED SCI, V24, P533
  6. EPELBAUM R, 1990, CANCER-AM CANCER SOC, V66, P1124, DOI 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T
  7. European Medicines Agency (EMA), 2015, VELC 3 5 MG POWD SOL
  8. Hirakawa T, 2010, ANN HEMATOL, V89, P897, DOI 10.1007/s00277-010-0956-7
  9. Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288
  10. Hu B, 2017, INT J CLIN PHARM TH, V55, P329, DOI 10.5414/CP202714
  11. KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963
  12. McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046
  13. Millennium Pharmaceuticals Inc, 2014, VELCADE BORT INJ SUB
  14. Pettengell R, 2008, ANN HEMATOL, V87, P429, DOI 10.1007/s00277-008-0447-2
  15. Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096
  16. Terada Y, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-116
  17. Mateos MV, 2015, AM J HEMATOL, V90, P314, DOI 10.1002/ajh.23933
  18. Yamaguchi H, 2011, J CLIN EXP HEMATOP, V51, P1, DOI 10.3960/jslrt.51.1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03